Teva Pharmaceutical Industries (NYSE:TEVA) Now Covered by HC Wainwright

Key Points

• HC Wainwright initiated coverage of Teva Pharmaceutical Industries with a “buy” rating and a $52 price target, implying 23.6% upside from the reported $42.07 share price.
• Analyst sentiment is broadly positive: 13 analysts rate Teva a Buy, one rates it Hold, and one rates it Sell. The consensus rating is “Moderate Buy,” with an average price target of $46.54.
• Teva shares were near a one-year high, while insiders sold approximately $14.6 million of stock over the prior 90 days; institutional investors own 54.05% of the company.

Analysts at HC Wainwright assumed coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) in a research report issued to clients and investors on Monday, Briefing.com reports. The firm set a "buy" rating and a $52.00 price target on the stock. HC Wainwright's target price suggests a potential upside of 23.60% from the stock's current price.

TEVA has been the subject of a number of other research reports. TD Cowen assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Thursday, October 1st. They set a "buy" rating and a $55.00 price objective for the company. Oppenheimer increased their target price on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an "outperform" rating in a research note on Friday, October 9th. Weiss Ratings raised Teva Pharmaceutical Industries from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, October 8th. Barclays boosted their price target on Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the company an "overweight" rating in a research note on Thursday, October 15th. Finally, JPMorgan Chase & Co. upped their price target on Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the company an "overweight" rating in a report on Monday, October 12th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $46.54.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $42.07 on Monday. The company has a debt-to-equity ratio of 1.56, a current ratio of 0.88 and a quick ratio of 0.67. Teva Pharmaceutical Industries has a one year low of $19.98 and a one year high of $42.59. The company has a fifty day moving average price of $39.07 and a 200 day moving average price of $34.55. The stock has a market cap of $49.02 billion, a P/E ratio of 70.12, a PEG ratio of 3.90 and a beta of 0.89.

Insider Transactions at Teva Pharmaceutical Industries

In related news, insider Brian Savage sold 7,342 shares of the company's stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $38.85, for a total value of $285,236.70. Following the sale, the insider owned 8,500 shares of the company's stock, valued at $330,225. The trade was a 46.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Roberto Mignone sold 367,600 shares of the stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $39.06, for a total transaction of $14,358,456.00. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 374,959 shares of company stock valued at $14,644,285 over the last ninety days. 0.54% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TEVA. Root Financial Partners LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter worth approximately $33,000. Cornerstone Planning Group LLC boosted its stake in Teva Pharmaceutical Industries by 547.1% in the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company's stock valued at $27,000 after buying an additional 755 shares in the last quarter. Western Wealth Management LLC bought a new stake in Teva Pharmaceutical Industries in the first quarter valued at $43,000. Sunbelt Securities Inc. bought a new stake in Teva Pharmaceutical Industries in the first quarter valued at $45,000. Finally, CX Institutional bought a new stake in Teva Pharmaceutical Industries in the second quarter valued at $54,000. Institutional investors own 54.05% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world's largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva's portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.